In the INDIGO Phase III trial (NCT04164901), Vorasidenib extended progression-free survival (27.7 vs. 11.1 months) in grade 2 IDH-mutant gliomas, leading to FDA approval in August 2024 despite manageable elevations in ALT, a marker of liver toxicity [158]. Here, IDH2 is linked to central nervous system cancer.